Solid Tumor Profiling

Identifying genomic alterations in solid tumors provides critical information about tumor biology that can ultimately determine treatment selection. The Anwa Solid Tumour Profiling panel uses next-generation sequencing (NGS) technology to rapidly detect somatic mutations in solid tumors, facilitating precise detection of actionable and targetable mutations in numerous cancers, including lung, colorectal, breast, thyroid, and brain.

The profile boasts a high specificity, sensitivity, and reproducibility providing the accuracy necessary to make a confident and appropriate diagnosis and determine the prognosis. The rapid turnaround combined with the precise detection of genetic alterations and the ability to catalog the unique genetic alterations present in each tumor facilitates timely, fully-individualized treatment selection for every patient.

Anwa Comprehensive Cancer Genomic Profile

This comprehensive NGS panel enables the analysis of variants across 500+ genes, targeting the most relevant cancer driver genes specifically chosen for their high rates of clinically significant mutations. This single assay identifies multiple biomarker types, including gene fusions, insertion/deletions (indels), single nucleotide variants (SNV), copy number variation (CNV), tumor mutational burden (TMB), microsatellite instability (MSI), and gene fusions. This assay will help guide the selection of targeted therapy and immunotherapies according to the most recent FDA, NCCN, and ESMO guidelines.

500 Genes

Unstained FFPE slides

10 working days

Anwa Focused Cancer Genomic Profile

Our focused NGS panel allows for the detection of hotspots, SNVs, indels, CNV, and gene fusion in 52 genes that are related to solid tumors including BRAF, EGFR, KRAS, ERBB2/3/4, ALK MET, and more.

52 genes

Liquid Biopsy (Blood Sample)

Unstained FFPE slides

10 working days